High Early Recurrence Rates With Merkel Cell Carcinoma High Early Recurrence Rates With Merkel Cell Carcinoma
The overall 5-year recurrence rate of this rare, aggressive skin cancer was 40% in a prospective cohort study.Medscape Medical News (Source: Medscape Internal Medicine Headlines)
Source: Medscape Internal Medicine Headlines - March 3, 2022 Category: Internal Medicine Tags: Dermatology News Source Type: news

Skin Cancer App Fails to Identify Rare, Aggressive Cancers
Sensitivity and specificity for detecting Merkel cell carcinoma and amelanotic melanoma was 79.4 and 37.7 percent, respectively (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - October 14, 2021 Category: Cancer & Oncology Tags: Dermatology, Family Medicine, Internal Medicine, Oncology, Pathology, Conference News, Source Type: news

Mohs Surgery Favorable as Monotherapy for Early Merkel Cell Mohs Surgery Favorable as Monotherapy for Early Merkel Cell
The findings add to a growing body of literature supporting Mohs for many types of rare tumors.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 2, 2021 Category: Consumer Health News Tags: Dermatology News Source Type: news

Oncotarget: Predictors of immunotherapy benefit in Merkel cell carcinoma
(Impact Journals LLC) Dr. Glenn J. Hanna from CCR/NCI in Bethesda, MD as well as The Dana-Farber Cancer Institute in Boston Massachusetts said, " Merkel cell carcinoma (MCC) is a relatively rare cancer, with roughly 400 cases per 100,000 persons each year in the United States " . (Source: EurekAlert! - Social and Behavioral Science)
Source: EurekAlert! - Social and Behavioral Science - March 22, 2021 Category: International Medicine & Public Health Source Type: news

Immunotherapy Should Be First Line in Merkel Cell Carcinoma Immunotherapy Should Be First Line in Merkel Cell Carcinoma
Pembrolizumab demonstrated durable tumor control, a generally manageable safety profile, and favorable survival outcomes compared with historical data in advanced MCC.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - March 18, 2019 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Tumor Control Durable With Pembrolizumab in Merkel Cell Cancer
28 of 50 advanced MCC patients responded; 24 - month overall survival rate was 68.7 percent (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - February 27, 2019 Category: Cancer & Oncology Tags: Dermatology, Oncology, Pharmacy, Journal, Source Type: news

Tumor Control Durable With Pembrolizumab in Merkel Cell Cancer
WEDNESDAY, Feb. 27, 2019 -- For patients with advanced Merkel cell carcinoma (aMCC), pembrolizumab is associated with durable tumor control and favorable overall survival, according to a study published online Feb. 7 in the Journal of Clinical... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - February 27, 2019 Category: Pharmaceuticals Source Type: news

Immunotherapy drug used as 1st-line therapy for Merkel cell carcinoma improved survival
(Louisiana State University Health Sciences Center) A multi-center phase II clinical trial investigating pembrolizumab as a first-line and programmed cell death-1 therapy in patients with advanced Merkel cell carcinoma reports lasting tumor control, generally manageable side effects and improved overall survival. Dr. Adam Riker led the study at LSU Health New Orleans. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - February 7, 2019 Category: International Medicine & Public Health Source Type: news

Immunotherapy appears better than chemotherapy for aggressive type of skin cancer
(Johns Hopkins Medicine) The first study of the immunotherapy drug pembrolizumab as the initial treatment for patients with a rare but aggressive form of skin cancer known as Merkel cell carcinoma reports better responses and longer survival than expected with conventional chemotherapy. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - February 7, 2019 Category: International Medicine & Public Health Source Type: news

Skin Cancer | Medscape Skin Cancer | Medscape
Nonmelanoma skin cancer primarily comprises basal cell carcinoma and squamous cell carcinoma. Other, rarer types of nonmelanoma skin cancer include dermatofibrosarcoma protuberans, Merkel cell carcinoma, and Kaposi ' s sarcoma. (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 28, 2018 Category: Consumer Health News Tags: Resource Center Source Type: news

Is First-Line Avelumab Effective for Metastatic Merkel Cell Carcinoma?
Investigators shared results of an interim analysis evaluating antitumor activity and safety in patients with mMCC receiving  avelumab monotherapy. (Source: CancerNetwork)
Source: CancerNetwork - November 14, 2018 Category: Cancer & Oncology Authors: John Schieszer Source Type: news

Skin Cancer Merkel Cell Carcinoma
Skin Cancer: Merkel Cell Carcinoma (Source: eMedicineHealth.com)
Source: eMedicineHealth.com - July 19, 2018 Category: General Medicine Source Type: news

Incidence of Merkel Cell Carcinoma Rising Sharply
The incidence of Merkel cell carcinoma, an aggressive neuroendocrine skin cancer, has grown rapidly since the disease was first described in 1972. (Source: CancerNetwork)
Source: CancerNetwork - March 23, 2018 Category: Cancer & Oncology Authors: Leah Lawrence Tags: News Skin Cancer Source Type: news

Aggressive Skin Cancer Rates Skyrocketing Aggressive Skin Cancer Rates Skyrocketing
The incidence of Merkel cell carcinoma is increasing exponentially as the US population ages, a new national study shows.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - February 19, 2018 Category: Consumer Health News Tags: Dermatology News Source Type: news

Immunotherapy for Merkel cell carcinoma -- novel research highlights quality of life benefits
(Future Science Group) Researchers have presented the association between tumor response and health-related quality of life in patients with metastatic Merkel cell carcinoma treated with avelumab. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - December 11, 2017 Category: International Medicine & Public Health Source Type: news